Clinical Trial Update: S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC） [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating 9 months of S-1 therapy versus 12 months in stage II gastric cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer | Phase 3 | Status: RECRUITING